A detailed history of Corient Capital Partners, LLC transactions in Seagen Inc. stock. As of the latest transaction made, Corient Capital Partners, LLC holds 2,728 shares of SGEN stock, worth $0. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,728
Previous 2,675 1.98%
Holding current value
$0
Previous $474,000 1.9%
% of portfolio
0.04%
Previous 0.04%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$135.27 - $180.11 $7,169 - $9,545
53 Added 1.98%
2,728 $483,000
Q2 2022

Aug 12, 2022

BUY
$108.81 - $179.33 $56,798 - $93,610
522 Added 24.25%
2,675 $474,000
Q1 2022

May 16, 2022

BUY
$119.61 - $157.85 $8,731 - $11,523
73 Added 3.51%
2,153 $310,000
Q4 2021

Feb 11, 2022

BUY
$142.57 - $190.86 $19,246 - $25,766
135 Added 6.94%
2,080 $322,000
Q3 2021

Nov 16, 2021

BUY
$142.45 - $169.82 $17,236 - $20,548
121 Added 6.63%
1,945 $330,000
Q2 2021

Aug 16, 2021

BUY
$135.08 - $161.1 $17,695 - $21,104
131 Added 7.74%
1,824 $288,000
Q1 2021

May 17, 2021

BUY
$137.51 - $190.8 $38,915 - $53,996
283 Added 20.07%
1,693 $235,000
Q4 2020

Feb 12, 2021

BUY
$164.63 - $211.93 $232,128 - $298,821
1,410 New
1,410 $247,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Corient Capital Partners, LLC Portfolio

Follow Corient Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corient Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Corient Capital Partners, LLC with notifications on news.